Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/201926
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Puerta Alcalde, Pedro | - |
dc.contributor.author | Monzó Gallo, Patricia | - |
dc.contributor.author | Aguilar-Guisado, Manuela | - |
dc.contributor.author | Ramos, Juan Carlos | - |
dc.contributor.author | Laporte Amargós, Júlia | - |
dc.contributor.author | Machado, Marina | - |
dc.contributor.author | Martín Davila, Pilar | - |
dc.contributor.author | Franch Sarto, Mireia | - |
dc.contributor.author | Sánchez Romero, Isabel | - |
dc.contributor.author | Badiola, Jon | - |
dc.contributor.author | Gómez, Lucia | - |
dc.contributor.author | Ruiz Camps, Isabel | - |
dc.contributor.author | Yáñez, Lucrecia | - |
dc.contributor.author | Vázquez, Lourdes | - |
dc.contributor.author | Chumbita, Mariana | - |
dc.contributor.author | Marco, Francesc | - |
dc.contributor.author | Soriano Viladomiu, Alex | - |
dc.contributor.author | González, Pedro | - |
dc.contributor.author | Fernández Cruz, Ana | - |
dc.contributor.author | Batlle, Montserrat | - |
dc.contributor.author | Fortún, Jesús | - |
dc.contributor.author | Guinea, Jesús | - |
dc.contributor.author | Gudiol, Carlota | - |
dc.contributor.author | García, Julio | - |
dc.contributor.author | Ruiz Pérez de Pipaón, Maite | - |
dc.contributor.author | Alastruey Izquierdo, Ana | - |
dc.contributor.author | García Vidal, Carolina | - |
dc.date.accessioned | 2023-09-13T12:16:55Z | - |
dc.date.available | 2023-09-13T12:16:55Z | - |
dc.date.issued | 2023-05-16 | - |
dc.identifier.issn | 1532-2742 | - |
dc.identifier.uri | http://hdl.handle.net/2445/201926 | - |
dc.description.abstract | Objectives: We describe the current epidemiology, causes, and outcomes of breakthrough invasive fungal infections (BtIFI) in patients with haematologic malignancies.Methods: BtIFI in patients with & GE; 7 days of prior antifungals were prospectively diagnosed (36 months across 13 Spanish hospitals) according to revised EORTC/MSG definitions.Results: 121 episodes of BtIFI were documented, of which 41 (33.9%) were proven; 53 (43.8%), probable; and 27 (22.3%), possible. The most frequent prior antifungals included posaconazole (32.2%), echinocandins (28.9%) and fluconazole (24.8%)-mainly for primary prophylaxis (81%). The most common haematologic malignancy was acute leukaemia (64.5%), and 59 (48.8%) patients had undergone a hematopoietic stem-cell transplantation. Invasive aspergillosis, principally caused by non-fumigatus Aspergillus, was the most fre-quent BtIFI with 55 (45.5%) episodes recorded, followed by candidemia (23, 19%), mucormycosis (7, 5.8%), other moulds (6, 5%) and other yeasts (5, 4.1%). Azole resistance/non-susceptibility was commonly found. Prior antifungal therapy widely determined BtIFI epidemiology. The most common cause of BtIFI in proven and probable cases was the lack of activity of the prior antifungal (63, 67.0%). At diagnosis, antifungal therapy was mostly changed (90.9%), mainly to liposomal amphotericin-B (48.8%). Overall, 10 0-day mor-tality was 47.1%; BtIFI was either the cause or an essential contributing factor to death in 61.4% of cases.Conclusions: BtIFI are mainly caused by non-fumigatus Aspergillus, non-albicans Candida, Mucorales and other rare species of mould and yeast. Prior antifungals determine the epidemiology of BtIFI. The exceed-ingly high mortality due to BtIFI warrants an aggressive diagnostic approach and early initiation of broad-spectrum antifungals different than those previously used.& COPY; 2023 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). | - |
dc.format.extent | 8 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier BV | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.jinf.2023.05.005 | - |
dc.relation.ispartof | Journal of Infection, 2023, vol. 87, num. 1, p. 46-53 | - |
dc.relation.uri | https://doi.org/10.1016/j.jinf.2023.05.005 | - |
dc.rights | cc by (c) Puerta Alcalde, Pedro et al., 2023 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Hematologia | - |
dc.subject.classification | Micosi | - |
dc.subject.other | Hematology | - |
dc.subject.other | Mycosis | - |
dc.title | Breakthrough invasive fungal infection among patients with haematologic malignancies: A national, prospective, and multicentre study | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-09-05T13:15:24Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 37201859 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
PIIS0163445323002633.pdf | 1.68 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License